TAIPEI, June 8, 2026 /PRNewswire/ -- GIGABYTE, the world's leading computer brand, continues to advance motherboard innovation by pushing its performance to a new...
TAIPEI, June 7, 2026 /PRNewswire/ -- GIGABYTE, the world's leading computer brand, continues to advance motherboard innovation by pushing its performance to a new...
TAIPEI, June 7, 2026 /CNW/ -- GIGABYTE, the world's leading computer brand, continues to advance motherboard innovation by pushing its performance to a new...
SHANGHAI, June 2, 2026 /PRNewswire/ -- Mouser Electronics, Inc., the authorized global distributor with the newest electronic components and industrial automation products, is proud...
MAS Pathfinder Programme listing reflects Finnate's governance-focused design and real-world deployment maturity across regulated financial servicesMELBOURNE, Australia, June 8, 2026 /PRNewswire/ -- Centelon announced that...
Ingelheim, Germany - Boehringer Ingelheim today announced positive results from two global Phase III trials of its glucagon/GLP-1 dual agonist survodutide (BI 456906), SYNCHRONIZE-1 and SYNCHRONIZE-MASLD.2,4 The results demonstrate survodutide’s potential to reduce weight and therefore improve metabolic health in two distinct populations: adults living with obesity or overweight, without type 2 diabetes (SYNCHRONIZE-1),2 and adults with overweight or obesity with metabolic dysfunction-associated steatotic liver disease (MASLD) with evidence of inflammation and or fibrosis (SYNCHRONIZE-MASLD).4 Full results from SYNCHRONIZE-1 and SYNCHRONIZE-MASLD were presented today at the American Diabetes Association’s (ADA) 2026 Scientific Sessions and published simultaneously in The New England Journal of Medicine and Nature Medicine respectively.5,6
Injectable Offers Potential to Reduce Fatty Liver Diseases and Improve Health Markers in AdultsNEW ORLEANS, June 7, 2026 /PRNewswire/ -- New data highlight the potential...
MONROE, N.J. and RANCHO CUCAMONGA, Calif., June 7, 2026 /PRNewswire/ -- For 12 years, MimiSilk, the at-home beauty device brand, has remained committed to a single...
MONROE, N.J. and RANCHO CUCAMONGA, Calif., June 7, 2026 /PRNewswire/ -- For 12 years, MimiSilk, the at-home beauty device brand, has remained committed to a single...
$45 Million Facility Honors Legendary Alumnus and Elevates the Future of Mustang FootballSAN LUIS OBISPO, Calif., June 6, 2026 /PRNewswire/ -- Cal Poly Athletics...
An independent, research-informed evaluation of the Her Bodhi botanical formula — examining its ingredient benefits, weight loss positioning, menopause wellness support, disclosed side effects, and publicly available consumer feedback.
An independent, research-informed evaluation of the Her Bodhi botanical formula — examining its ingredient benefits, weight loss positioning, menopause wellness support, disclosed side effects, and publicly available consumer feedback.
New research supports monthly dosing as a next‑generation opportunity to improve weight lossNEW ORLEANS, June 6, 2026 /PRNewswire/ -- New data highlight the potential...